A new generative AI startup, Bioptimus, has emerged in Paris with a unique focus on applying AI models to the field of biology.
Unlike other AI startups, Bioptimus faces different challenges due to the sensitive nature of the clinical data it needs to train its models. To address these challenges, the startup has raised a significant $35 million seed round led by Sofinnova Partners along with several other notable investors.
Notably, Bioptimus has a team led by Jean-Philippe Vert and Rodolphe Jenatton, both of whom bring extensive experience in AI and biotech from their respective roles at companies like Owkin and Google.
Image Credits: Bioptimus
By leveraging extensive patient data from partnerships with leading academic hospitals, Bioptimus aims to train its foundational model and contribute to advancements in disease diagnosis, precision medicine, and the development of new biomolecules for medical and environmental use.
A moonshot project from Owkin
Bioptimus is considered a moonshot project spun off from Owkin, addressing the need for a separate entity to focus on the complex task of building foundational AI models for biology.
Partnering with Amazon Web Services, Bioptimus signals its readiness to train its AI model in Amazon’s data centers, suggesting a high level of ambition and potential for impact within the biotech research community.
